or Try an Advanced Search...

    Advanced Solid Tumors Stocks List

    Symbol Grade Name % Change
    ELEV D Elevation Oncology, Inc. 4.15
    CASI D CASI Pharmaceuticals, Inc. -0.19
    IMRX F Immuneering Corporation 3.43
    SLRX F Salarius Pharmaceuticals, Inc. 4.29
    CRDF F Cardiff Oncology, Inc. -1.19
    CLRB F Cellectar Biosciences, Inc. 1.28
    ADCT F ADC Therapeutics SA -2.02
    HOWL F Werewolf Therapeutics, Inc. 8.54
    PPBT F Purple Biotech Ltd. 2.83
    RLAY F Relay Therapeutics, Inc. -0.43
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research
    Related Stock Lists: Solid Tumors Cancer Medicine Biotechnology Clinical Medicine Oncology Antineoplastic Drugs Cancer Treatment Life Sciences Lymphoma Ovarian Cancer Treatment Of Cancer Autoimmune Disease Biopharmaceutical Chemotherapy Drugs Leukemia Metastatic Solid Tumors Pharmaceutical Prostate Cancer

    Related ETFs - A few ETFs which own one or more of the above listed Advanced Solid Tumors stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 1.86
    LRNZ A TrueMark Technology, AI & Deep Learning ETF 0.8
    CANC D Tema Oncology ETF 0.69
    BBC F Virtus LifeSci Biotech Clinical Trials ETF 0.57
    SCDS B JPMorgan Fundamental Data Science Small Core ETF 0.28
    View all Advanced Solid Tumors ETFs...
    Compare ETFs
    Compare CNCR to BBC Compare CNCR to CANC Compare LRNZ to CANC

        Advanced Solid Tumors Stocks Recent News

        Date Stock Title
        Nov 20 RLAY Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 20 HOWL Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
        Nov 19 RLAY Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 19 CRDF Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
        Nov 19 CLRB Q3 2024 Cellectar Biosciences Inc Earnings Call
        Nov 18 CLRB Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
        Nov 18 CLRB Cellectar Biosciences GAAP EPS of -$0.40 misses by $0.03
        Nov 18 CLRB Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
        Nov 18 CLRB Earnings Scheduled For November 18, 2024
        Nov 17 CASI CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
        Nov 15 CLRB Cellectar Biosciences Q3 2024 Earnings Preview
        Nov 15 CASI CASI Pharmaceuticals reports Q3 results
        Nov 15 CASI CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
        Related Industries: Biotechnology Diagnostics & Research
        Related Stock Lists: Solid Tumors Cancer Medicine Biotechnology Clinical Medicine Oncology Antineoplastic Drugs Cancer Treatment Life Sciences Lymphoma Ovarian Cancer Treatment Of Cancer Autoimmune Disease Biopharmaceutical Chemotherapy Drugs Leukemia Metastatic Solid Tumors Pharmaceutical Prostate Cancer
        Advanced Solid Tumors

        Advanced solid tumors are cancerous tumors that have spread beyond the original site of the tumor and have become more difficult to treat. These tumors are often referred to as metastatic or stage IV tumors. Advanced solid tumors can affect any part of the body and can be caused by a variety of different types of cancer. Treatment options for advanced solid tumors may include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and/or clinical trials.

        Browse All Tags